With their small particle size, large specific surface area, magnetic response, and superparamagnetism, magnetic nanoparticles [MNPs] are a type of intelligent nano-magnetic material [1].  The electromagnetic wave in the alternating magnetic field absorbs the heat when MNPs are assembled and placed in a continuous magnetic field.  MNPs are typically found in the superparamagnetic state in biomedical applications [2,3].  Iron oxide nanoparticles, such as magnetite [Fe3O4] and maghemite [γ‑Fe2O3], are the most commonly used nanomaterials [4].  MNPs are known to play a significant role in the diagnosis, delivery, and treatment of cancer.  Tumor imaging technology made early disease detection possible for the diagnosis of cancer. Magnetic resonance imaging [MRI] [5], computed tomography [CT] [7], magneto acoustic tomography [MAT] [6], and near-infrared [NIR] imaging [8] are examples of common imaging modalities.  Superparamagnetic iron oxide nanoparticles, or SPIONs, are the most representative contrast agent for MRI among them, and MRI plays a significant role in the early diagnosis of cancer [9].  Some iron oxide-based MNPs are currently authorized for use in clinical MRI; for instance, ferumoxil [Gastro MARK] improves bowel imaging [10].  MNPs can easily reach the lesion site because of their small size and large specific surface area [11].  Consequently, it is impossible to overlook the use of MNPs as drug carriers for drug delivery. When used as drug delivery agents, MNPs’ ability to target drugs to a specific location in vivo through the application of an external magnetic field is fully utilized [12].  MNPs typically bind to chemotherapeutic drugs [14], as well as antibodies [13] to serve as drug carriers.  MNPs are frequently loaded with chemotherapeutic medications, which are used to treat cancer.  Chemotherapy, magnetic hyperthermia [MHT] [15], photodynamic therapy [PDT] [16], and photothermal therapy [PTT] [17] are the main ways that MNPs are used in the field of cancer therapy.  Combination therapy is typically employed to improve the therapeutic effect. A framework for the use of MNPs in medicine, including cancer diagnosis, medication delivery, and treatment, is presented in this review.  Along with the possible difficulties and opportunities, nanotoxicity is also reviewed.

The diagnosis of cancer

Early cancer detection significantly increases the chance of recovery.  Therefore, the key to lowering the patient mortality rate is early detection and prompt diagnosis of cancer [18].  The decision to use a late-generation magneto motive photoacoustic with cyclic magnetic motion and ultrasound speckle tracking, whose imaging capture frame rate is several hundred times faster than the previously proven photoacoustic speckle tracking method, is crucial for the diagnosis of cancer.  In order to use NIR imaging to observe the NP fate within a biofilm, Stone et al. demonstrated a magnetic NP system.Furthermore, using a mouse model of orthotopic mammary cancer, Xi et al. [27] demonstrated a breast imaging method that combines high-resolution NIR light-induced photoacoustic tomography [PAT] with NIR dye-labeled amino-terminal fragments of urokinase plasminogen activator receptor-targeted magnetic iron oxide NPs [NIR830‑ATF‑IONP] for breast cancer imaging. MPI [29] and ultrashort echo time [UTE] imaging [28] have been shown in other studies to potentially enhance the detection of MNPs in cancer. Other imaging techniques are combined with MRI for MNPs.  This dual imaging technique could increase diagnosis accuracy.  For example, pancreatic and breast [30] cancers have been treated with dual imaging using single-photon emission computed tomography [SPECT] and magnetic resonance imaging [MRI].  The synthesis and application of monodisperse iron oxide nanoparticles coated with fluorescent silica nanoshells for fluorescence and magnetic resonance dual imaging of tumors were demonstrated in a study by Jang e [31].  Additionally, Sun et al. [32] used optical imaging [OI] and magnetic resonance imaging [MRI] to diagnose breast cancer.

Pancreatic imaging position

Because of its late presentation, pancreatic cancer is one of the most deadly cancers worldwide [33]. Consequently, patients will have a higher chance of recovery with an early diagnosis. Survivin antisense oligonucleotides [ASON] and chitosan-coated MNPs are conjugated to produce Sur-MNPs, which function in tandem with ASON to cause targeted localization in pancreatic tumors [34]. Pancreatic tumors could be detected by MRI using survivin-targeted NPs. Biodegradable NPs were created using recombinant human serum albumin and iron oxide [maghemite, γ-Fe2O3], taking into consideration the more sensitive diagnostic tools to enable early medical imaging. SPECT-CT and MRI showed improved imaging and targeting capabilities in mice.

Imaging techniques
MRI

MRI has been regarded as one of the most valuable noninvasive imaging techniques due to its high spatial resolution and tomographic capabilities [19], and MNPs have recently been proposed as an alternative to MRI [20]. Generally speaking, conducting surface modification of nanoparticles [NPs] by inducing the magnetic dipole interaction and its intrinsic surface energy is required to overcome the colloidal instability of MNPs. PEGylated folic acid [FA] and fluoresce in isothiocyanate [FI] were successively added to water-dispersible polyethylene imine [PEI]-coated Fe3O4 nanoparticles [NPs] through PEI-mediated conjugation chemistry [21]. The colloidally stable FA-functionalized Fe3O4 NPs for MRI were created by acetylating the remaining PEI surface amines. In MRI, studies have shown that sensitive imaging of superparamagnetic NPs or aggregates may detect early lesions in a 6-year-old boy with glioblastoma multiforme [22]. Additionally, the study showed that the multifunctional nanocomposites showed promise for combining diagnostic and therapeutic properties [23].

Additional imaging techniques

According to a study by Mariappan, magneto acoustic tomography estimates an image of the distribution of the NPs in vivo with ultrasound imaging resolution by using a short pulsed magnetic field to induce ultrasound in tissue that has been SPION-labeled. High spatial resolution and sensitivity are made possible by magnetic particle imaging [MPI], a technique similar to atomographic imaging. According to a study by Lindeman et al. [24] University of Luebeck Dextran-coated SPIONs are promising tracer materials for use in novel tumor cell analysis in MPI. Additionally, as a potential imaging tool, photoacoustic imaging has drawn more attention. A study by Lietal [25–34] created a new.

The breast

Some guidelines for designing a the imaging device for MNPs to improve the microwave imaging of breast cancer were outlined in a study by Bucci et al. [35]. The findings showed that, when designed in accordance with the established guidelines, MNP-enhanced microwave imaging may accurately detect cancer lesions even with low-complexity arrangements. According to a study by Kato et al [36], liposome encapsulation greatly enhanced the delivery and retention of SPIONs in breast tumors. Targeted SPION liposomes also significantly enhanced accumulation in breast tumors, making them potentially the best choice for MRI breast tumor detection. Sun et al demonstrated that more peptide cyclic-arginine-glycine-aspartic acid [RGD]-FMNPs accumulated around the tumors than FMNPs when magnetic nanoclusters coated with ruthenium [II] complexes doped with silica [fluorescent magnetic nanoparticles, or FMNPs] were used. The findings suggested that RGD-FMNPs could be used as a targeting molecular probe for MRI and OI-based breast cancer detection. Bevacqua and Scapaticci [37] used a compressive sensing technique for three-dimensional breast cancer in order to make a more precise and targeted diagnosis of the disease.

The prostate

MRI is the recommended imaging modality for patients with prostate cancer because it offers the best soft tissue resolution and plays a significant role in the management of prostate cancer [38]. After injecting radiolabeled tracers, lympho scintigraphy is frequently used to evaluate the sentinelly lymph node [SLN] in patients with prostate cancer. For instance, patients used T1‑, T2‑, and T2*‑weighted sequences for MRI at 1.5T before and 1 day after SPION injection. This was the first study to visualize SLNs by MRI in patients with prostate cancer using intraprostatic injection of SPIONs [39]. According to a study by Winter et al. [40], it is safe, practicable, and consistently detects lymph node metastases and SLNs in the majority of patients when SPIONs are injected transrectally intraprostatically for magnetic marking in prostate cancer. In other situations, the Gleason score, a histological indicator of prostate cancer aggressiveness, correlates with the sensitivity of diffusion-weighted [DW] MRI to water diffusion throughout tissues [41].

Lung

Wan et al. [42] developed immune SPIONs for use in magnetic resonance immune imaging to increase the sensitivity of lung cancer metastasis detection. After coating these SPIONs with carboxymethyl dextran and oleic acid, they were conjugated to a mouse anti-cluster of differentiation [CD]44v6 monoclonal antibody. Lung tumor-targeting diagnosis may benefit from the prepared SPIONs. Additionally, targeted pulmonary inhalation aerosol-based delivery has inherent benefits and makes it easier to administer medications directly to the lungs in a controlled manner [43]. Therefore, using small animal experiments, Nishimo et al. [46–52] examined the viability of applying MPI to pulmonary imaging using nebulized MNPs and to quantify the mucociliary clearance in the lung [53-55].

Other
The prostate, breast, and pancreas are commonly treated with common contrast agents. In other situations, a range of imaging modalities are used in conjunction with the diagnosis and treatment, as described in.

Delivery of drugs

Magnetically targeted drug delivery has been used to decrease side effects and enhance the therapeutic efficacy of medications used in traditional cancer treatment. MNPs with a stabilizing shell coating have been effectively employed as MRI contrast agents [56]. Early diagnosis may allow for simultaneous treatment, which could significantly increase efficiency. MNPs are therefore crucial to drug delivery. MNPs can be employed as drug carriers by binding antibodies, chemotherapy, or other medications.

Antibodies
Because of their high-level accumulation within cancer cells, research has shown that antibody-conjugated MNPs may be used to treat ovarian cancer in addition to detecting ovarian cancer biomarkers [57,58]. For the first time, a study by Wang et al. revealed that HAI-178 monoclonal antibody [mAb] conjugated fluorescent MNPs, an anti-α subunit of adenosine triphosphate synthase antibody, was successfully used for targeted imaging and simultaneous therapy of invivogastric cancer. Regarding human breast cancer, Shanehsazzadeh et al [59] showed disappointing in vivo results when conjugating ultra-small SPIONs with C595 mAb, with very little accumulation of nanoprobes in the targeted site. In contrast, a study by Rasaneh and Dadras [60] proposed that combining MNPs with a permanent magnet could improve the therapeutic efficacy of herceptin for greater accumulation in the tumor site. Combining antibodies with chemotherapeutic medications is becoming more and more popular as a way to increase therapeutic efficacy. A new multifunctionalized iron oxide MNP with anti-CD44 antibody and gemcitabine derivatives was presented in a study by Aires et al. [61] along with their use for the selective treatment of CD44-positive cancer cells. Furthermore, Huangtal [62] created a novel cancer dual-targeting treatment that uses magnetic Fe3O4 nanoparticles grafted with single-chain antibodies and β-cyclodextrin loaded with docetaxel. These studies have shown how effective the combination of chemotherapeutic medications and antibodies can be.

Chemotherapy medication

As listed in Table II, common chemotherapy medications include doxorubicin [DOX], paclitaxel, cisplatin, gemcitabine, methotrexate, docetaxel, and sorafenibandmitomycin C. The most commonly used chemotherapy medication in targeted delivery systems is DOX [63]. MNPs' stability is limited due to their hydrophobic coating [64]. A reducible copolymer self-assembled with SPIONs was created to deliver DOX for cancer treatment in order to address this problem [14]. Michael addition was used to create the copolymer of reducible polyamidoamine with polyethylene glycol/dodecyl amine graft [14]. Furthermore, studies have shown that the use of iron oxide MNPs enhanced DOX-NP cell penetration in comparison to free DOX and produced an acellular response to DOX-NP conjugates that was comparable to that of DOX alone [65]. Additionally, SPIONs have been studied as a targeted drug delivery vehicle. For instance, Chichaetal [66–75] established an in vitro system to examine the various facets of cellular reactions to mitoxantrone-carrying [76–84].

Other

Some traditional Chinese medicine products have been used as anti-cancer medications in targeted drug delivery in addition to chemotherapy drugs. The fabrication and characterization of dendrimerized MNPs as epigallocate-echingallate delivery vectors were presented in a study by Nigam and Bahadur [85]. Curcumin has recently been widely used in the drug delivery of MNPs in breast cancer. In a study by Mancarella et al. [86], Fe3O4 NPs were functionalized layer by layer by coating them in Dextran and Poly[L-lysine], which resulted in a high upload of curcumin in Fe3O4 NPs for the treatment of ovarian cancer. Additionally, it has been shown that magnetic Fe3O4@hydroxyapatite‑PEI‑b‑cyclodextrin NPs and magnetic Fe3O4@zirconium phosphate core‑shell NPs are efficient drug carriers for the delivery of curcumin, and both have been used to treat breast cancer [87,88]. In other situations, oligonucleotides are used in drug delivery. In a study by Pourianazar and Gunduz [89], they used three-layer MNPs made of a cationic poly [amidoamine] dendrimer, an aminosilane interlayer, and a Fe3O4 magnetic core to improve the accumulation of CpG oligodeoxynucleotide molecules in tumor cells as a novel targeted delivery system. Additionally, 2-amino-2-deoxyglucose was conjugated to COOH-modified cobalt ferrite MNPs, which were intended to target tumor cells as a possible targetable drug/gene delivery agent for the treatment of cancer [90]. In conclusion, MNPs might offer a highly effective drug delivery method that could lead to drug targeting.

Treatment for cancer

The ultimate objective of MNPs as drug carriers is to treat. This section discusses and provides examples of the use of MNPs in MHT, PDT, PTT and combined treatment.

MHT

Because of its possible medical applications, MHT has garnered a lot of attention lately. Electromagnetic energy can be transformed into heat by MNPs [91]. Thus, heating tumor cells to their apoptosis threshold is probably the most common use for MNPs [92]. Important factors that may increase the effectiveness of heat generation for cancer therapy at low NP treatment doses include magnetic field strength and frequency, NP size, NP concentration, and solution viscosity [93]. The in vivo anti-tumor effect under a low-frequency magnetic field using MNPs has not yet been demonstrated, despite the fact that MNPs represent an area of active development for MHT.
The in vivo anti-tumor effect under a low-frequency magnetic field using MNPs has not yet been demonstrated, despite the fact that MNPs represent an area of active development for MHT. A study by Cheng et al. [94] showed that glioma cells could be successfully destroyed in vitro and in vivo using spin-vortex, disk-shaped permalloymagnetic particles in a low-frequency, rotating magnetic field. Furthermore, hysteresis loss is crucial for MHT since it improves heating efficiency [94]. The hysteresis loss of magneti-cally fractionated MNPs for use in hyperthermia was investigated in a study by Sasayama et al. [95]. They came to the conclusion that magnetically separating MNPs increases the efficiency of hyperthermia [95]. In general, MHT may somewhat increase the effectiveness of chemotherapeutic medications. For example, the therapeutic effects of MHT in breast cancer could be significantly increased by combining SPIONs [MF66] that are functionalized with Nucant multivalent pseudopeptide [N6L], DOX, and MHT [96]. Additionally, dual-functional Pt-Fe-hydroxyapatite MNPs were created for the treatment of lung cancer by chemo-hyperthermia [97]. Furthermore, studies have shown that MHT of MNPs improved radiation treatment in human prostate cancer murine models [98]. In other situations, gene delivery plays a significant part in MHT as well [99,100].

PDT
PDT is a minimally invasive, externally activated cancer treatment method. Photosensitizing drugs, also known as photosensitizers [PSs], are applied either locally or systemically as part of the PDT process. The PSs are then photoexcited in the tissue using light of the proper wavelength and power. When oxygen is present, the PS is excited from its ground state to its excited state after being activated by light of the proper wavelength. An electron is then transferred to the oxygen in the surrounding tissue, creating excited single oxygen or oxygen free radicals. These chemicals, also referred to as reactive oxygen species [ROS], harm cells and eventually cause tissue damage in cancer. Building a targeted drug delivery system with MNPs has gained attention as a way to increase the impact of PSs. For example, Park et al. synthesized multifunctional cobalt ferrite [CoFe2O4] nanoparticles [NPs] [CoFe2O4‑hematoporphyrins [HPs]‑FAs] and functionalized them by conjugating with FA to target cancer cells and coating them with HP to introduce photo-functionality. Additionally, other studies have shown that the Fe3O4@HP particles showed strong anti-cancer effects on human prostate cancer [PC-3] and breast cancer [MDA-MB-231] cell lines, as well as remarkable and effective photodynamic anticancer activity. For PDT, pyrophorbide-a [PPA] as anovelchlorin PS was prepared. Fe3O4@SiO2@ CS@PPA [MFCSPPA], a PPA-coated multifunctional magneto-fluorescent nanoparticle, was designed. The experiments showed that MFCSPPA had low dark toxicity and strong photodynamic therapy activity. After receiving PDT, the cell viability of human HeLa cervical cancer cells dropped to 18%.

PTT
Because of its light toxicity to the skin and deep tissue penetration, NIR may kill cancer cells directly by PTT, which is now a controlled treatment method. PTT, which uses photothermalagents in conjunction with NIR, has also drawn more attention as a cancer treatment option. Engineering phosphopeptide-decorated MNPs as effective photothermal agents for solid tumor therapy is one example of this. Notably, the photothermal effect of MNP clusters was first documented for the in vivo and in vitro photothermal ablation [PTA] of tumors. Clustered Fe3O4 NPs may lead to a significant increase in NIR absorption when compared to individual magnetic Fe3O4 NPs. Clustered Fe3O4NPs that produced higher temperatures upon NIR irradiation at 808 nm were more cytotoxic to A549 cells. PTT and MRI are typically performed in tandem. But according to a study, small Fe3O4 NPs showed more cellular internalization than their large counterparts, which allowed for a higher PTA efficacy in vitro. Furthermore, the ideal diameter of Fe3O4 NPs for MRI and PAT in vitro may be nm. As a result, MNP size may be a significant PTT factor.

Combination Therapy

MNPs typically serve as drug carriers for systems of targeted delivery. For combined cancer PTT and PDT, the nanocomplex containing PSs and PTT agents may be utilized. The first use of magnetic-optical hybrid nanosystems for dual mode PTT and PDT and magnetic-field-guided drug delivery was shown in a study by Bhana et al. Under NIR laser irradiation, the composite NPs may produce heat and ROS concurrently, and they may even be delivered to the mitochondria specifically. Moreover, MNPs have been shown to have the dual ability to enhance heating efficiency by acting as both magnetic and PTT agents. In summary, these findings showed a significant accumulation of MNPs in superior

APPLICATIONS

Other groups have created and improved magnetic micro- and nanoparticle-based drug and gene delivery systems since the work of Widder and others, with differing degrees of success. Doxor-ubicin was coupled to magnetic particles and targeted to sarcomatumors implanted in rats in the first study by Widder and others, and the method has proven successful in a number of animal studies. The control group, which received ten times the dosage but no magnetic targeting, showed no signs of remission, while the magnetic-targeting group experienced complete remission. Numerous other animal studies, not just involving small animals, have reported tumor remission. such as rats and rabbits [e.g., Alexio Pulfer], but also larger pigs, and one study had increased the targeting depth to about 10 cm. Recently, Alexiou and colleagues used HPLC analysis of mitoxantrone bound to ferrofluids to successfully quantify the distribution of magnetically targeted carriers in a rabbit model. They also used light microscopy to show that magnetically targeted carriers are absorbed in HeLa cells in vitro. Kubo and others installed permanent magnets at solid osteosarcoma sites in hamsters, followed by the delivery of cytotoxic compounds via magnetoliposomes, in an attempt to address issues with the spatial configuration of these delivery systems. Compared to standard intravenous [non-magnetic] delivery, this led to a fourfold increase in drug delivery to the tumor site. The group also reported a significant increase in anti-tumor activity and a decrease in side effects related to weight loss. Another possible solution to the geometry problem is suggested by theoretical and experimental analysis of implanted magnetic grids for targeting the heart muscle. Despite two Phase I/II clinical trials, the use of magnetic targeting in humans has not yet reached the market. Lu¨bbe and others conducted a Phase I clinical trial on 14 patients. Although targeting was examined in detail, particle accumulation was seen in the tumor masses of six of the patients. This was primarily done to assess the potential toxicity of the particle-carrier complex. The study showed that magnetic carriers are generally well tolerated, even though the particles accumulated in the heliver.

Magnetic Nanoparticles/Carriers

There are a number of methods for creating magnetic nanoparticles for drug delivery. It is possible to produce particles with a core-shell structure, in which the core is a magnetic iron oxide [typically magnetite [Fe3O4] or maghemite [gFe2O3]], and the shell is typically a polymer like silica, dextran, or PVA, or metals like gold to which functional groups can be attached via cross. Both ionic and non-ionic surfactant techniques can be used to synthesize this kind of structure, or it can be encapsulated within a structure like a carbon cage or ferritin protein [for example, see Meldrum et al., Carboxyl groups, amines, biotin, streptavidin, antibodies, and other substances can then be attached to these particles to functionalize them.
Several groups have created methods for the synthesis of magnetoliposomes in addition to these polymers. These nanoparticles have an unusual core-shell structure, with an artificial liposome encircling a magnetic iron oxide core. These are typically used to treat magnetic hyperthermia, but they could also be helpful for drug delivery. Additionally, particles can be incorporated into hydrogels to carry a therapeutic agent that is released upon heating, or the particles themselves can be used for applications involving hyperthermia. Lao and Ramanujan, Chenetal More recently, 5–25 nm-sized gold/cobalt nanoparticles with a core-shell structure and a customizable shape have been created. The rapid breakdown of organic precursors in the presence of surfactants, which regulate the particles' size and shape, has produced these particles. One of these particles' main advantages is that cobalt has a magnetic moment that is almost twice as high as that of magnetite or maghemite. The precipitation of magnetic iron oxide nanoparticles within an aporous polymer micro-ornanoparticle scaffold is another method for creating magnetic/polymer nanoparticles. One benefit of this technique is that it makes it possible to create particles with a well-defined, spherical shape and a relatively tight size distribution. As with core-shell structures, the particles can be functionalized to allow for the attachment of drugs or the embedding of therapeutic compounds within a biodegradable polymer.

CONCLUSION

As imaging contrast agents, MNPs have a lot of promise for adjuvant treatment. However, numerous limitations have been placed on the use of MNPs because of the toxicity that has been linked to their use. It is well known that MNP surface coatings affect both the beneficial properties and possible toxicity of MNPs. Studies have shown that the accumulation in vivo increases with the size of the MNPs. Consequently, regulating MNPs' surface coatings and size may lessen toxicity and enhance their magnetic properties. In this review, we concentrated on MNP-assisted drug delivery, cancer diagnosis through imaging, and cancer treatment. There are still certain difficulties even after numerous successful studies employing MNPs as a catheter-like substance. Even though a lot of MNP formulations have shown great results in small animal models, they fall short of the clinical standard. MNPs may be able to be used clinically with integrated imaging and multimodal therapy in the near future and have a significant impact on cancer treatment if their drug loading capacity is improved and their specificity and affinity to target cancer cells are increased.

REFERENCES

1.      Briguet A, Jeandey C and Tournier E: System of coils for producing additional fields for obtaining polarization fields with constant gradients in a magnet having polarization pole pieces for image production by nuclear magnetic resonance. Journal, 1988.

2.      hyperthermia increases iron oxide nanoparticle cell association/uptake and flux in blood‑brain barrier models. Pharm Res 32: 1615-1625, 2015.

3.      Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil‑IcetaL, Alonso E, González Esparza M, Gómez‑VallejoV, Szczupak B, et al: Targeted diagnostic magnetic nanoparticles formedicalimagingofpancreaticcancer.JControlRelease214: 76-84, 2015.

4.      Lu AH, Zhang XQ, Sun Q, Zhang Y, Song Q, Schüth F, Chen C and Cheng F: Precise synthesis of discrete and dispersible carbon‑protected magnetic nanoparticles for efficient magnetic resonance imaging and photothermal therapy. Nano Res 9: 1460-1469, 2016.

5.      Mariappan L, Shao Q, Jiang C, Yu K, Ashkenazi S, Bischof JC and He B: Magneto acoustic tomography with short pulsed magnetic field for in‑vivo imaging of magnetic iron oxide nanoparticles. Nanomedicine 12: 689-699, 2016.

6.      FitzGerald PF, Butts MD, Roberts JC, Colborn RE, Torres AS, Lee BD, Yeh BM and Bonitatibus PJ Jr: A proposed computed tomography contrast agent using carboxy betaine zwitter ionic tantalum oxide nanoparticles: Imaging, biological and physico- chemical performance. Invest Radiol 51: 786‑796, 2016.

7.      Stone RC, Fellows BD, Qi B, Trebatoski D, Jenkins B, Raval Y, Tzeng TR, Bruce TF, Mc Nealy T, Austin MJ,etal: Highly stable multi‑anchored magnetic nanoparticles for optical imaging within biofilms. J Colloid Interface Sci 459: 175-182, 2015.

8.      Zhou Q and Wei Y: Forbet terorworse, iron over load by super- paramagnetic iron oxide nanoparticles as a MRI contrast agent for chronic liver diseases. Chem Res Toxicol 30: 73-80, 2017.

9.      Tse BW, Cowin GJ, Soekmadji C, Jovanovic L, Vasireddy RS, Ling MT, KhatriA, Liu T, Thierry B and Russell PJ: PSMA‑targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine [Lond] 10: 375-386, 2015.

10.   Ahmed M and Douek M: The role of magnetic nanoparticlesin the localization and treatment of breast cancer. Biomed Res Int 2013: 281230, 2013.

11.   Wang C, Bao C, Liang S, Zhang L, Fu H, Wang Y, Wang K,Li C, Deng M, Liao Q, et al: HAI‑178 antibody‑conjugated fluorescent magnetic nanoparticles for targeted imaging and simultaneous therapy of gastric cancer. Nanoscale Res Lett 9: 274, 2014.

12.   Chen J, Shi M, Liu P, Ko A, Zhong W, Liao W and Xing MM: Reducible polyamidoamine‑ magnetic iron oxide self‑assembled nanoparticles for doxorubicin delivery. Biomaterials 35: 1240-1248, 2014.

13.   Yin PT, Shah BP and Lee KB: Combined magnetic nanopar- ticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells. Small 10: 4106‑4112, 2014.

14.   Li L, Nurunnabi M, Nafiujjaman M, Jeong Y Y ,Lee Y k and Huh K M: A photosensitizer‑conjugated magnetic iron oxide/gold hybrid nanoparticle as an activatable platform for photodynamic cancer therapy. J Mat Chem B 2: 2929‑2937, 2014.

15.   Shen S, Wang S, Zheng R, Zhu X, Jiang X, Fu D and Yang W: Magnetic nanoparticle clusters for photothermal therapy with near‑infrared irradiation. Biomaterials 39: 67-74, 2015.

16.   Zhang H, Li J, Hu Y, Shen M, Shi X and Zhang G: Folic acid‑targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer.J Ovarian Res 9: 19, 2016.

17.   Luo Y, Yang J, Yan Y, Li J, Shen M, Zhang G, Mignani S and Shi X: RGD‑functionalized ultra small iron oxide nanoparticles for targeted T₁‑weighted MR imaging of gliomas. Nanoscale 7: 14538-14546, 2015.

18.   Yadollahpour A, Hosseini SA, Rashidi S and Farhadi F: Applications of magnetic nanoparticles as contrast agents in MRI: Recent advances and clinical challenges. Int J Pharm Res Allied Sci, 2016.

19.   LiJ, Hu Y, Yang J, Sun W, Cai H,Wei P, SunY, Zhang G,Shi X and Shen M: Facile synthesis of folic acid‑functionalized iron oxide nanoparticles with ultrahigh relaxivity for targeted tumor MR imaging. J Mater Chem B 3: 5720-5730, 2015.

20.   LiZ, Hsu CH, Dimitrov N, Hwang DW, Chang HW, Hwang LP and Lin YY: Sensitive imaging of magnetic nanoparticles for cancer detection by active feedback MR. Magn Reson Med: Apr 4, 2015 [Epub ahead of print].

21.   YangZ, Ding X and Jiang J: Facile synthesis of magnetic-plasmonic nano composites as T₁ MRI contrast enhancing and photothermal therapeutic agents. Nano Res 9: 787-799, 2016.

22.   Lindemann A, Lüdtke‑ Buzug K, Fräderich BM, Gräfe K, Pries R and Wollenberg B: Biological impact of super paramagnetic iron oxide nanoparticles for magnetic particle imaging of head and neck cancer cells. Int J Nanomedicine 9: 5025-5040, 2014.

23.   Li J, Arnal B, Wei CW, Shang J, Nguyen TM, O'Donnell Mand Gao X: Magneto‑optical nanoparticles for cyclic magneto- motive photoacoustic imaging. ACS Nano 9: 1964-1976, 2015.

24.   Jaeger M, Preisser S, Kitz M, Ferrara D, Senegas S, Schweizer D and Frenz M: Improved contrast deep optoacoustic imaging using displacement-compensated averaging: Breast tumour phantom studies. Phys Med Biol 56: 5889-5901, 2011.

25.   Xi L, Grobmyer SR, Zhou G, Qian W, Yang L and Jiang H: Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents. J Biophotonics 7: 401-409, 2014.

26.   Wang L, Zhong X, Qian W, Huang J, Cao Z, Yu Q, Lipowska M, Lin R, Wang A, Yang Land Mao H: Ultra shortecho time [UTE] imaging of receptor targeted magnetic iron oxide nanoparticles  in mouse tumor models .J Magn Reson Imaging 40:1071-1081, 2014.

27.   Nishimoto K, Mimura A, Aoki M, Banura N and Murase K: Application of magnetic particle imaging to pulmonary imaging using nebulized magnetic nanoparticles. Open J Med Imag 5: 49, 2015.

28.   Deng S, Zhang W, Zhang B, Hong R, Chen Q, Dong J, Chen Y, Chen Z and Wu Y: Radio labeled cyclic arginine-glycine-aspartic [RGD]‑conjugated iron oxide nanoparticles as single‑photon emission computed tomography [SPECT] and magnetic resonance imaging [MRI] dual‑modality agents for imaging of breast cancer. J Nano Res 17: 19, 2015 .

29.   Sun J, Teng ZG, Tian Y, Wang JD, Guo Y, Kim DH, Larson AC and Lu GM: Targeted fluorescent magnetic nanoparticles for imaging of human breast cancer. Int J ClinExp Med 7: 4747-4758, 2014.

30.   Karelia D, Pandey MK, Irby R, Amin S and Sharma AK: Suppression of pancreatic cancer cell growthby NISC‑6 through activation of Par‑4 and death receptor 5. Exp Mol Ther 73, 2013.

31.   Wang Z, Tong M, Chen X, Hu S, Yang Z, Zhang Y, Zhou H, Wu Y, Li X and Li D: Survivin‑ targeted nanoparticles for pancreatic tumor imaging in mouse model. Nanomedicine 12: 1651-1661, 2016.

32.   Bucci OM, Crocco L and Scapaticci R: On the optimal measurement configuration for magnetic nanopar- ticles‑enhanced breast cancer microwave imaging. IEEE Trans Biomed Eng 62: 407-414, 2015.

33.   Kato Y, Zhu W, Backer MV, Neoh CC, Hapuarachchige S, Sarkar SK, Backer J Mand Artemov D: Noninvasive imaging of liposomal delivery of super paramagnetic iron oxide nanopar- ticles to orthotopic human breast tumor in mice. Pharm Res32: 3746-3755, 2015.

34.   Bevacqua MT and Scapaticci R: A Compressive sensing approach for 3D breast cancer microwave imaging with magnetic nanoparticles as contrast agent. IEEE Trans Med Imaging 35: 665-673, 2016.

35.   Guneyli S, Erdem CZ and Erdem LO: Magnetic resonance imaging of prostate cancer. Clin Imaging 40: 601-609, 2016.

36.   Winter A, Kowald T, Paulo T, Goos P, Engels S, Gerullis H, Chavan A and Wawroschek F: 1060 Magnetic resonance sent in lymph node imaging in prostate cancer using intraprostatic injection of super paramagnetic iron oxide nanoparticles: The first in‑human results. Europ Urol Suppl 15: e1060, 2016.

37.   Winter A, Woenkhaus J and Wawroschek F: 979 Magnetic marking and intraoperative detection of primary draining lymph nodes in prostate cancer using intraprostaticinjection of super paramagnetic iron oxide nanoparticles. Europ UrolSuppl 14: e979, 2015.

38.   Hill DK, Kim E, Teruel JR, Jamin Y, Widerøe M, Søgaard CD, Størkersen Ø, Rodrigues DN, Heindl A, Yuan Y, et al: Diffusion‑weighted MRI for early detection and character- ization of prostate cancer in the transgenic adenocarcinoma of the mouse prostate model. J Magn Reson Imaging 43:1207-1217, 2016.

39.   Wan X, Song Y, Song N, Li J, Yang L, Li Y and Tan H: The preliminary study of immune super paramagnetic iron oxide nanoparticles for the detection of lung cancer in magnetic resonance imaging. Carbohydr Res 419: 33-40, 2016

40.   Stocke NA, Meenach SA, Arnold SM, Mansour H M and Hilt JZ: Formulation and characterization of inhalable magnetic nano composite microparticles [MnMs] for targeted pulmonary delivery via spray drying.Int JPharm479:320-328, 2015.

41.   Wang D, Fei B, Halig LV, Qin X, Hu Z, Xu H, Wang YA, Chen Z, Kim S, Shin DM and Chen ZG: Targeted iron‑oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. ACS Nano 8: 6620-6632, 2014.

42.   Bhattacharya D, Behera B, Sahu SK, Ananthakrishnan R, Maiti TK and Pramanik P: Design of dual stimuli responsive polymer modified magnetic nanoparticles for targeted anti‑cancer drug delivery and enhanced MR imaging. New J Chem 40: 545‑557, 2016.

43.   Pilapong C, Sitthichai S, Thongtem S and Thongtem T: Smart magnetic nanoparticle‑ aptamer probe for targeted imaging and treatment of hepatocellular carcinoma. Int J Pharm 473: 469-474, 2014.

44.   Wu M, Zhang D, Zeng Y, Wu L, Liu X and Liu J: Nano cluster of super paramagnetic iron oxide nanoparticles coated with poly [dopamine] for magnetic field‑targeting, highly sensitive MRI and photo thermal cancer therapy. Nanotechnology 26: 115102, 2015.

45.   Azhdarzadeh M, Atyabi F, Saei A A, Varnamkhasti BS, Omidi Y, Fateh M, Ghavami M, Shanehsazzadeh S and Dinarvand R: The ranostic MUC‑1 aptamer targeted gold coated super para- magnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer. Colloids Surf B Biointerfaces 143: 224-232, 2016.

46.   Kim KS, Kim J, Lee JY, Matsuda S, Hideshima S, Mori Y, Osaka T and Na K: Correction: Stimuli-responsive magnetic nanoparticles for tumor‑targeted bimodal imaging and photo- dynamic/hyperthermia combination therapy. Nanoscale 8: 12843, 2016.

47.   Sun L, Joh DY, Al‑Zaki A, Stangl M, Murty S, Davis JJ, Baumann BC, Alonso‑Basanta M, Kaol GD, Tsourkas A and Dorsey JF: Theranostic application of mixed gold and super- paramagnetic iron oxide nanoparticle micelles in glioblastomamultiforme. J Biomed Nanotechnol 12: 347-356, 2016.

48.   Zhao X, Chen Z, Zhao H, Zhang D, Tao L and Lan M: Multifunctional magnetic nanoparticles for simultaneous cancer near‑infrared imaging and targeting photodynamic therapy. RSC Adv 4: 62153‑62159, 2014.

49.   Khalkhali M, Rostamizadeh K, Sadighian S, Khoeini F,Naghibi M and Hamidi M: The impact of polymer coatings on magnetite nanoparticles performance as MRI contrast agents:A comparative study. Daru 23: 45, 2015.

50.   Pal MK, Rashid M and Bisht M: Multiplexed magnetic nanoparticle‑antibody conjugates [MNPs‑ABS] based prog- nostic detection of ovarian cancer biomarkers, CA‑125, β-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance [SPR] analysis. Biosens Bioelectron 73: 146-152, 2015.

51.   Ndong C, Toraya‑Brown S, Kekalo K, Baker I, Gerngross TU, Fiering SN and Griswold KE: Antibody‑mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo. Int J Nanomedicine 10: 2595-2617, 2015.

52.   Shanehsazzadeh S, Gruettner C, Lahooti A, Mahmoudi M, Allen BJ, Ghavami M, Daha F Jand Oghabian MA: Monoclonal antibody conjugated magnetic nanoparticles could targetMUC-1-positive cells in vitro but not in vivo. Contrast Media Mol Imag 10: 225-236, 2014

53.   .Rasaneh S and Dadras MR: The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibody. Biomed Tech [Berl] 60: 485-490, 2015.

54.   Aires A, Ocampo SM, Simões BM, Josefa Rodríguez M, Cadenas JF, Couleaud P, Spence K, Latorre A, Miranda R, Somoza Á, et al: Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44‑positive cancer cells. Nanotechnology 27: 065103, 2016.

55.   Huang X, Yi C, Fan Y, Zhang Y, Zhao L, Liang Z and Pan J: Magnetic Fe₃O₄ nanoparticles grafted with single‑chain antibody [scFv] and docetaxel loaded β‑cyclodextrin potential for ovarian cancer dual‑targeting therapy. Mat Sci Eng. C 42: 325-332, 2014.

56.   JiaY, Yuan M, Yuan H, Huang X, Sui X, Cui X, Tang F, Peng J, Chen J, Lu S, et al: Co‑encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nano- carriers for intratumoral drug delivery. Int J Nanomedicine 7: 1697-1708, 2012.

57.   Singh M, Ulbrich P, Prokopec V, Svoboda P, Šantavá E and Štěpánek F: Effect of hydrophobic coating on the magnetic anisotropy and radiofrequency heating of γ‑Fe2O3 nanopar- ticles. J Magnet Magn Mat 339: 106-113, 2013.

58.   Augustin E, Czubek B, Nowicka AM, Kowalczyk A, Stojek Z and Mazerska Z: Improved cytotoxicity and preserved level of cell death induced in colon cancer cells by doxorubicin after its conjugation with iron‑oxide magnetic nanoparticles. Toxicol In Vitro 33: 45‑53, 2016.

59.   Cicha I, Scheffler L, Ebenau A, Lyer S, Alexiou C and Goppelt‑Struebe M: Mitoxantrone‑loaded superparamagnetic iron oxide nanoparticles as drug carriers for cancer therapy: Uptake and toxicity in primary human tubular epithelial cells. Nanotoxicology 10: 557‑566, 2016.

60.   Zohreh N, Hosseini SH and Pourjavadi A: Hydrazine‑modified starch coated magnetic nanoparticles as an effective pH‑responsive nanocarrier for doxorubicin delivery. J Indus Eng Chem 39: 203-209, 2016.

61.   Frounchi M and Shamshiri S: Magnetic nanoparticles‑loaded PLA/PEG microspheres as drug carriers. J Biomed Mater Res A 103: 1893-1898, 2015.

62.   Pilapong C, Keereeta Y, Munkhetkorn S, Thongtem S and Thongtem T: Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles. Colloids Surf B: Bio 113: 249‑253, 2014.

63.   Wu J, Wang Y, Jiang W, Xu S and Tian R: Synthesis and char- acterization of recyclable clusters of magnetic nanoparticles as doxorubicin carriers for cancer therapy. Appl Surf Sci 321: 43‑49, 2014.

64.   Chandra S, Noronha G, Dietrich S, Lang H and Bahadur D: Dendrimer-magnetic nanoparticles as multiple stimuli responsive and enzymatic drug delivery vehicle. J Magn Magn Mat 380: 7‑12, 2015.

65.   Hałupka ‑ Bryl M, Bednarowicz M, Dobosz B, Krzyminiewski R, Zomasz T, Wereszczyńska B, Nowaczyk G ,Jarek Mand Nagasaki Y: Doxorubicin loaded PEG‑b‑poly[4‑vinyl benzyl phosphonate] coated magnetic iron oxide nanoparticles for targeted drug delivery. J Magn Magn Mat 384: 320-327, 2015.

66.   Zou Y, Liu P, Liu CH and Zhi XT: Doxorubicin‑loaded meso- porous magnetic nanoparticles to induce apoptosis in breast cancer cells. Biomed Pharm 69: 355‑360, 2015.

67.   Tansık G, Yakar A and Gündüz U: Tailoring magnetic PLGA nanoparticles suitable for doxorubicin delivery. J Nano Res 16: 2171, 2014.

68.   Ghorbani M, Hamishehkar H, Arsalani N and Entezami AA: Surface decoration of magnetic nanoparticles with folate‑conjugated poly [N‑isopropylacrylamide‑co‑itaconic acid]: A facial synthesis of dual‑responsive nanocarrier for targeted delivery of doxorubicin. Int J Poly Mat Poly Bio 65: 683‑694, 2016.

69.   Mangaiyarkarasi R, Chinnathambi S, Karthikeyan S, Aruna P and Ganesan S: Paclitaxel conjugated Fe3O4@LaF3:Ce3+,Tb3+ nanoparticles as bifunctional targeting carriers for Cancer theranostics application. J Magn Magn Mat 399: 207-215, 2016.

70.   Lin MM, Kang YJ, Sohn Y and Kim DK: Dual targeting strategy of magnetic nanoparticle‑loaded and RGD peptide‑activated stimuli‑sensitive polymeric micelles for delivery of paclitaxel. J Nano Res 17: 248, 2015.

71.   Fazilati M: Anti‑neoplastic applications of heparin coated magnetic nanoparticles against human ovarian cancer. J Inorg Organ Poly Mat 24: 551‑559, 2014.

72.   Parsian M, Unsoy G, Mutlu P, Yalcin S, Tezcaner A and Gunduz U: Loading of gemcitabine on chitosan magnetic nanoparticles increases the anti‑cancer efficacy of the drug.Eur J Pharmacol 784: 121-128, 2016.

73.   Roy E, Patra S, Madhuri R and Sharma PK: Stimuli‑responsive poly [N-isopropyl acrylamide]-co-tyrosine@ gadolinium: Iron oxide nanoparticle‑based nanotheranostic for cancer diagnosis and treatment. Coll Surf B: Bio 142: 248‑258, 2016.

74.   Nagesh PK, Johnson NR, Boya VK, Chowdhury P, Othman SF, Khalilzad‑ Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW, et al: PSMA targeted docetaxel‑loaded super- paramagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces 144: 8-20, 2016.

75.   Li YJ, Dong M, Kong FM and Zhou JP: Folate‑decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics. Int J Pharm489: 83-90, 2015.

76.   Türkmen D, Bereli N, Çorman ME, Shaikh H, Akgöl S and Denizli A: Molecular imprinted magnetic nanoparticles for controlled delivery of mitomycin C. Artif Cells Nanomed Biotechnol 42: 316-322, 2014.

77.   Unsoy G, Yalcin S, Khodadust R, Mutlu P, Onguru O and Gunduz U: Chitosan magnetic nanoparticles for pH responsive Bortezomib release in cancer therapy. Biomed Pharmacother 68: 641-648, 2014.

78.   Nigam S and Bahadur D: Dendrimerized magnetic nanopar- ticles as carriers for the anticancer compound, epigallocate chingallate. IEEE Transact on Magn 52: 1‑5, 2016.

79.   Mancarella S, Greco V, Baldassarre F, Vergara D, Maffia M andLeporattiS:Polymer-coated magnetic nanoparticles for curcumin delivery to cancer cells. Macromol Biosci15: 1365-1374, 2015.

80.   Kalita H, Rajput S, Kumar BP, Mandal Mand Pathak A:Fe3O4@ zirconium phosphate core‑shell nanoparticles for pH‑sensitive and magnetically guided drug delivery applications.RSC Adv 6: 21285-21292, 2016.

81.   Akrami M, Khoobi M, Khalilvand‑Sedagheh M, Haririan I, Bahador A, Faramarzi MA, Rezaei S, Javar HA, Salehi F, Ardestani SK and Shafiee A: Evaluation of multilayer coated magnetic nanoparticles as biocompatible curcumin delivery platforms for breast cancer treatment. RSCAdv5:88096-88107, 2015.

82.   Pourianazar NT and Gunduz U: Cp Goligodeoxynu- cleotide-loaded PAMAM dendrimer-coated magnetic nanoparticles promote apoptosis in breast cancer cells. Biomed Pharm 78: 81‑91, 2016.

83.   Aşık E,Aslan TN, Volkan Mand Güray NT: 2‑Amino‑2‑deoxy‑glucose conjugated cobalt ferrite magnetic nanoparticle [2DG‑MNP] as a targeting agent for breast cancer cells. Environ Toxicol Pharmacol 41: 272-278, 2016.

84.   Lee JH, Jang JT, Choi JS, Moon SH, Noh SH, Kim JW, Kim JG, Kim IS, Park KI and Cheon J: Exchange‑coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol 6: 418-422, 2011.

85.   Guibert C, Dupuis V, Peyre Vand Fresnais J: Hyperthermia of magnetic nanoparticles: Experimental study of the role of aggregation. J Phys Chem C 119: 28148‑28154, 2015.

86.   Shah RR, Davis TP, Glover AL, Nikles DE and Brazel CS: Impact of magnetic field parameters and iron oxide nanoparticle properties on heat generation for use in magnetic hyperthermia. J Magn Magn Mater 387: 96-106, 2015.

87.   Cheng Y, Muroski ME, Petit DCMC, Mansell R, Vemulkar T, Morshed RA, Han Y, Balyasnikova IV, Horbinski CM, Huang X, etal: Rotating magnetic field induced oscillation of magnetic particles for in vivo mechanical destruction of malignant glioma. J Control Release 223: 75-84, 2016.

88.   Sasayama T, Yoshida T, Tanabe K, Tsujimura Nand Enpuku K: Hysteresis loss of fractionated magnetic nanoparticles for hyperthermia application. IEEE Trans Magn 51: 1‑4, 2015.

89.   Kossatz S, Grandke J, Couleaud P, Latorre A, Aires A, Crosbie‑Staunton K, Ludwig R, Dähring H, Ettelt V, Lazaro‑Carrillo A, et al: Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. Breast Cancer Res 17: 66, 2015.

90.   Tseng CL, Chang KC, Yeh MC ,Yang KC, Tang T Pand Lin FH: Development of a dual‑functional Pt‑Fe‑HA Pmagnetic nanoparticles application for chemo‑hyperthermia treatment of cancer. Ceram Int 40: 5117‑5127, 2014.

91.   Attaluri A, Kandala SK, Wabler M, Zhou H, Cornejo C,Armour M, Hedayati M, Zhang Y, De Weese TL, Herman Cand Ivkov R: Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer. Int J Hyperthermia 31: 359-374, 2015.

92.   Yin PT, Shah S, Pasquale NJ, Garbuzenko OB, Minko T and Lee KB: Stem cell‑based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer. Biomaterials 81: 46‑57, 2016.

93.   Yuan C, An Y, Zhang J, Li H, Zhang H, Wang L and Zhang D: Magnetic nanoparticles for targeted therapeutic gene delivery and magnetic-inducing heating on hepatoma. Nanotechnology 25: 345101, 2014.

94.   Cheng J, Tan G, Li W, Li J, Wang Z and Jin Y: Preparation, characterization and in vitro photodynamic therapy of a pyropheophorbide‑a‑conjugated Fe₃O₄ multifunctional magne- to fluorescence photosensitizer.RSCAdv6:37610-37620,2016.

95.   Hou W, Xia F, Alves CS, Qian X, Yang Y and Cui D: MMP2‑targeting andredox ‑responsive PEGylated chlorin e6 nanoparticles for cancer near‑infrared imaging and photo- dynamic therapy. ACS Appl MatInterfaces 8:1447‑1457,2016.

96.   Li H, Song S, Wang W and Chen K: In vitro photodynamic therapy based on magnetic-luminescent Gd2O3:Yb, Ernanoparticles with bright three‑photon up‑conversion fluorescence under near‑infrared light. Dalton Trans 44: 16081-16090, 2015.

97.   Park BJ, Choi KH, Nam KC, Ali A, Min JE, Son H, Uhm HS, Kim HJ, Jung JS and Choi EH: Photodynamic anticancer activities of multifunctional cobalt ferrite nanoparticles in various cancer

98.   Nam KC, Choi KH, Lee KD, Kim JH, Jung J S and Park BJ: Particle size dependent photodynamic anticancer activity of hematopor- phyrin‑ conjugated Fe₃O₄ particles. J Nanomaterial 2016:1,2016.

99.   Cheng J, Tan G, Li W, Zhang H, Wu X, Wang Z and Jin Y: Facile synthesis of chitosan assisted multifunctional magnetic Fe3O4@ SiO2@CS@pyropheophorbide‑a fluorescent nanoparticles for photodynamic therapy. New J Chem 40: 8522-8534, 2016.

100. Cheng L, Yang K, Chen Q and Liu Z: Organic stealth nanopar- ticles for highly effective in vivo near‑infrared photothermal therapy of cancer. ACS Nano 6: 5605-5613, 2012.